Doctors urgently need better international guidance on treating attention deficit hyperactivity disorder (ADHD) in the over 50s, conclude world-leading experts reviewing current research on this increasing issue globally.
Bristol Myers touts LAG-3 strategy in lung cancer as it preps for showdown with Merck’s Keytruda
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS